Compare Southern Copper Corp (SCCO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southern Copper Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Southern Copper Corp trades at $195 (market cap $166.96B), while Vertex Pharmaceuticals Incorporated trades at $528.01 (market cap $132.79B). The key difference: Southern Copper Corp is the larger of the two by market cap, and Southern Copper Corp pays a 2.23% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| SCCO | VRTX | |
|---|---|---|
Market Cap | $166.96B | $132.79B |
Sector | Basic Materials | Health |
52-Week High | $218.85 | $529.65 |
52-Week Low | $93.70 | $376.62 |
Enterprise Value | $168.25B | $126.92B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southern Copper (SCCO) trades at $199.06, up 3.12% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $2.01 vs. $1.98, revenue growth from $13.42B in 2025 to projected $15.8B in 2026, and exceptional profitability with 35.87% net margin. Recent corporate actions include dividends and stock splits, while institutional activity shows increased positions from Dimensional Fund Advisors and CalPERS.
SCCO presents growth potential driven by strong earnings performance and AI-driven copper demand, but faces risks from analyst skepticism (41.38% sell ratings) and valuation concerns with P/E of 29.51. The stock trades above consensus price target of $153.64, suggesting limited near-term upside despite positive technical momentum and fundamental strength.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
